The University of Pennsylvania Cancer Center is the largest and oldest institute of the University of Pennsylvania. Its mission is to facilitate multi-disciplinary, interdepartmental cancer research, education and patient care. Its mission is to facilitate multi-disciplinary, interdepartmental cancer research, education and Glick, MD, has directed the Cancer Center for 14 years. The Cancer Center's three Divisions (Fundamental Research, Clinical Research, and Population Science and Cancer Control) are comprised of inter-disciplinary Research Programs in: Immunobiology, Tumor Biology, Virology, Clinical Investigations, Melanoma, Pediatric Oncology, Radiation Biology, Gene Therapy in Cancer, Stem Cell Biology and Therapeutics, Neuro-Oncology, Breast Cancer, and Behavioral Sciences and Health Services Research Programs as well as a Developing Chemoprevention Program. This application includes 16 Shared Resources. The Flow Cytometry and Cell Sorting Facility, Nucleic Acid Facility, Melanoma Core, Biostatistics Unit and Clinical Research Unit are among the oldest NCI-funded cores. A wide range of research seminars and interdisciplinary laboratory space are used to facilitate member interaction and collaboration. Developmental Funds are critical to supporting faculty recruitment, innovative pilot projects that have the potential for peer-reviewed funding, translational research initiatives and Shared Resources. The development and expansion of Research Programs and Shared Resources, along with the recruitment of new faculty and acquisition of additional research space have all contributed to helping the Cancer Center reach its current level of excellence. A comprehensive, interactive strategic planning process has been instrumental in identifying future directions in cancer research, Research Programs and Shared Resources and allocation of resources. The Cancer Center continues to meet Comprehensiveness guidelines and was last fully approved for the maximum five-year period in 1995. Cancer Center members have $99.2 million in research and training in total costs (direct and indirect), of which $91 million is peer-reviewed and $35.4 million is from the National Cancer Institute.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016520-28
Application #
6619476
Study Section
Subcommittee G - Education (NCI)
Program Officer
Ciolino, Henry P
Project Start
1978-12-01
Project End
2004-11-30
Budget Start
2002-12-01
Budget End
2003-11-30
Support Year
28
Fiscal Year
2003
Total Cost
$5,315,570
Indirect Cost
Name
University of Pennsylvania
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Shroff, Rachna T; Hendifar, Andrew; McWilliams, Robert R et al. (2018) Rucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation. JCO Precis Oncol 2018:
Fraietta, Joseph A; Lacey, Simon F; Orlando, Elena J et al. (2018) Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat Med 24:563-571
Williams, Austin D; Reyes, Sylvia A; Arlow, Renee L et al. (2018) Is Age Trumping Genetic Profiling in Clinical Practice? Relationship of Chemotherapy Recommendation and Oncotype DX Recurrence Score in Patients Aged Ann Surg Oncol 25:2875-2883
Anton, Lauren; Sierra, Luz-Jeannette; DeVine, Ann et al. (2018) Common Cervicovaginal Microbial Supernatants Alter Cervical Epithelial Function: Mechanisms by Which Lactobacillus crispatus Contributes to Cervical Health. Front Microbiol 9:2181
Bengsch, Bertram; Ohtani, Takuya; Khan, Omar et al. (2018) Epigenomic-Guided Mass Cytometry Profiling Reveals Disease-Specific Features of Exhausted CD8 T Cells. Immunity 48:1029-1045.e5
Krump, Nathan A; Liu, Wei; You, Jianxin (2018) Mechanisms of persistence by small DNA tumor viruses. Curr Opin Virol 32:71-79
Bhagwat, Neha; Dulmage, Keely; Pletcher Jr, Charles H et al. (2018) An integrated flow cytometry-based platform for isolation and molecular characterization of circulating tumor single cells and clusters. Sci Rep 8:5035
Nair, Praful R; Alvey, Cory; Jin, Xiaoling et al. (2018) Filomicelles Deliver a Chemo-Differentiation Combination of Paclitaxel and Retinoic Acid That Durably Represses Carcinomas in Liver to Prolong Survival. Bioconjug Chem 29:914-927
Kasner, Margaret T; Mick, Rosemarie; Jeschke, Grace R et al. (2018) Sirolimus enhances remission induction in patients with high risk acute myeloid leukemia and mTORC1 target inhibition. Invest New Drugs 36:657-666
Raposo-Ferreira, Talita M M; Brisson, Becky K; Durham, Amy C et al. (2018) Characteristics of the Epithelial-Mesenchymal Transition in Primary and Paired Metastatic Canine Mammary Carcinomas. Vet Pathol 55:622-633

Showing the most recent 10 out of 1047 publications